Healio Rheuminations ANCA Vasculitis and the Complement System, Part 2: On to the Humans
The final episode summarizes the human data on complement in ANCA vasculitis, with a quick discussion of the trials of C5a receptor antagonism.
Brought to you by Actemra.
- Intro :10
- Welcome :21
- Recap of previous episodes :22
- In this episode 2:12
- Let’s start with neutrophil data 5:24
- Studies in humans 11:54
- A summary of the data so far 21:20
- What does all this amount to? 25:41
- Trials of avacopan 28:25
- Side effect profile 36:25
- Thanks for listening 37:06
Disclosures: Brown reports no relevant financial disclosures.
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum
References:
Augusto JF, et al. PLoS One. 2016;https://doi.org/10.1371/journal.pone.0158871.
Bekker P, et al. PLoS One. 2016;https://doi.org/10.1371/journal.pone.0164646.
Chen SF, et al. Arthritis Res Ther. 2015;https://doi.org/10.1186/s13075-015-0656-8.
Falk RJ, et al. Proc Natl Acad Sci USA. 1990;87:4115-4119.
Gou SJ, et al. Clin J Am Soc Nephrol. 2013;8:1884-1891.
Gou SJ, et al. Kidney Int. 2013;83:129-137.
Jayne DRW, et al. J Am Soc Nephrol. 2017;28:2756-2767.
Jayne DRW, et al. N Engl J Med. 2021;384:599-609.
Merkel PA, et al. ACR Open Rheumatol. 2020;2:662-671.